Sanofi is in the process of “finalizing” the sale to the American fund CD&R

Sanofi is finalizing discussions with the American fund CD&R for the sale of its subsidiary manufacturing Doliprane despite the improved offer proposed by a French competitor, confirmed the president of Sanofi France in an interview published on Saturday in Courrier Picard. “Following a traditional process, a partner was identified ten days ago. We are finalizing discussions with him. It’s a growth project», declared Audrey Duval, questioned about the improved offer announced Thursday by the French fund PAI for the buyout of its subsidiary Opella.

Thursday evening, the French pharmaceutical giant had already said “surprised» of this offer excluding “deadlines», recalling his choice of the previous week. Sanofi announced on October 11 that it was negotiating with the American investment fund CD&R in order to potentially sell it 50% of Opella, its subsidiary which houses around a hundred brands of non-prescription products around the world, including Doliprane.

This strategic project, a new example of the refocusing of “Big Pharma” on innovation, quickly took a political turn given the popularity of the drug used to relieve pain and fever within French society.